Table 3.
Treatment response and survival in NET G3
| Outcomes | CAPTEM (n = 20) | PRRT (n = 10) | EP (n = 8) | FOLFOX (n = 7) | Everolimus (n = 2) |
|---|---|---|---|---|---|
| Line of therapy, n (%) | |||||
| First | 10 (50.0) | 1 (10) | 4 (50.0) | 2 (28.6) | 0 (0.0) |
| Second | 10 (50.0) | 1 (10) | 3 (37.5) | 2 (28.6) | 1 (50.0) |
| Third or higher | 0 (0.0) | 8 (80) | 1 (12.5) | 3 (42.9) | 1 (50.0) |
| Best response, n (%) | |||||
| PR | 7 (35.0) | 2 (20.0) | 2 (25.0) | 2 (28.6) | 0 (0.0) |
| SD | 6 (30.0) | 5 (50.0) | 2 (25.0) | 2 (28.6) | 1 (50.0) |
| PD | 7 (35.0) | 3 (30.0) | 4 (50.0) | 3 (42.9) | 1 (50.0) |
| DCR | 13 (65.0) | 7 (70.0) | 4 (50.0) | 4 (57.1) | 1 (50.0) |
| ORR | 7 (35.0) | 2 (20.0) | 2 (25.0) | 2 (28.6) | 0 (0.0) |
| PFS, months (95% CI) | 9.40 (2.96–16.07) | 9.13 (3.42‐NR) | 2.94 (1.31–6.37) | 13.04 (0.89‐NR) | 1.23 (0‐NR) |
| OS, months (95% CI) | 41.23 (17.48‐NR) | NR (7.29‐NR) | 39.56 (2.10‐NR) | NR (8.28‐NR) | NR (NR‐NR) |
| Median follow‐up (n = 30), mo | 18.91 (1.64–47.80) | 18.91 (1.64–47.80) | 18.91 (1.64–47.80) | 18.91 (1.64–47.80) | 18.91 (1.64–47.80) |
Abbreviations: CAPTEM, capecitabine and temozolomide; CI, confidence interval; DCR, disease control rate; EP, Platinum‐etoposide; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; NET G3, well‐differentiated high‐grade neuroendocrine tumor; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression‐free survival; PR, partial response; PRRT, peptide radionuclide receptor therapy; SD, stable disease.